Edwards Lifesciences Corporation (EW) : The money flow analysis of Edwards Lifesciences Corporation (EW) indicates a $17.96 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $25.99 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.45 and so was the total money flow at $8.02 million. The bulls lapped up $7.99 million worth of block trades on upticks. The money flow was $7.99 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Edwards Lifesciences Corporation (EW), pushing it down by -0.01% for the day. The stock slid $0.01 and traded at $106.25 during the day. Nonetheless, the stock is 0.93% over the previous weeks close.
Edwards Lifesciences Corporation (EW) : Currently there are 14 street experts covering Edwards Lifesciences Corporation (EW) stock. The most bullish and bearish price target for the stock is $132 and $100 respectively for the short term. The average price target of all the analysts comes to $117.14. The estimated standard deviation from the target is $9.26.
Edwards Lifesciences Corporation (NYSE:EW): On Fridays trading session , Opening price of the stock was $106.2 with an intraday high of $106.5. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $105.28. However, the stock managed to close at $106.25, a loss of 0.01% for the day. On the previous day, the stock had closed at $106.26. The total traded volume of the day was 856,350 shares.
In a related news,The officer (CVP, Japan & Intercontinental) of Edwards Lifesciences Corp, Wang Huimin sold 13,650 shares at $98.44 on July 5, 2016. The Insider selling transaction had a total value worth of $1,343,706. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.